Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 18;26(14):6907.
doi: 10.3390/ijms26146907.

Identification of Genetic Variants Using Next-Generation Sequencing in Pediatric Myelodysplastic Syndrome: From Disease Biology to Clinical Applications

Viviane Lamim Lovatel  1 , Gerson Moura Ferreira  2 , Beatriz Ferreira da Silva  1 , Rayane de Souza Torres  1 , Rita de Cássia Barbosa da Silva Tavares  3 , Ana Paula Silva Bueno  4 , Eliana Abdelhay  2 , Teresa de Souza Fernandez  1
Affiliations

Identification of Genetic Variants Using Next-Generation Sequencing in Pediatric Myelodysplastic Syndrome: From Disease Biology to Clinical Applications

Viviane Lamim Lovatel et al. Int J Mol Sci. .

Abstract

This study aimed to identify genetic variants using a customized next-generation sequencing (NGS) panel for pediatric myelodysplastic syndrome (pMDS) and to explore their associations with cytogenetic and clinical characteristics. Cytogenetic analyses were conducted using G-banding and fluorescence in situ hybridization. NGS was performed with the Ion Torrent Personal Genome Machine for the following genes: GATA2, RUNX1, CEBPA, ANKRD26, ETV6, SAMD9, SAMD9L, PTPN11, NRAS, SETBP1, DDX41, TP53, FLT3, SRP72, and JAK3. Analyses were performed with Ion Reporter 5.20.8.0 software. Genetic variants were classified using the dbSNP, 1000 Genomes, COSMIC, and Varsome databases. We analyzed 25 cases of pMDS; 15 presented abnormal karyotypes, and 19 showed genetic variants. Among the 29 variants identified across 12/15 genes, 27% were pathogenic and 14% were likely pathogenic, with NRAS and GATA2 most frequently associated with disease progression. A new somatic variant of uncertain significance in SETBP1 was detected in seven patients showing heterogeneous clinical outcomes. Genetic variants were found in 7/10 patients with normal karyotypes, indicating that submicroscopic alterations can shed light on disease biology. Our results highlight the critical role of a targeted NGS panel in identifying molecular alterations associated with pMDS pathogenesis, thereby enhancing diagnostic precision, prognosis, and aiding in treatment selection.

Keywords: genetic variants; pediatric myelodysplastic syndrome; targeted NGS panel.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Overall clinical, cytogenetic, and genetic spectrum of pMDS patients. (A) The corresponding color coding is defined in the legend. P: pathogenic; LP: likely pathogenic; VUS: variant of uncertain significance; BM: bone marrow; RCC: refractory cytopenia of childhood; AML: acute myeloid leukemia; MDS-EB: myelodysplastic syndrome with excess of blasts. (B) The ribbon plot was created using Flourish [https://flourish.studio/ (accessed on 31 March 2025)], which shows the associations between cytogenetic profiles and genetic variants observed in the present study.
See this image and copyright information in PMC

References

    1. Chisholm K.M., Bohling S.D. Childhood Myelodysplastic Syndrome. Clin. Lab. Med. 2023;43:639–655. doi: 10.1016/j.cll.2023.06.005. - DOI - PubMed
    1. Arber D.A., Orazi A., Hasserjian R.P., Borowitz M.J., Calvo K.R., Kvasnicka H.-M., Wang S.A., Bagg A., Barbui T., Branford S., et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–1228. doi: 10.1182/blood.2022015850. - DOI - PMC - PubMed
    1. Bernard E., Tuechler H., Greenberg P.L., Hasserjian R.P., Ossa J.E.A., Nannya Y., Devlin S.M., Creignou M., Pinel P., Monnier L., et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1:EVIDoa2200008. doi: 10.1056/EVIDoa2200008. - DOI - PubMed
    1. Babcock S., Calvo K.R., Hasserjian R.P. Pediatric myelodysplastic syndrome. Semin. Diagn. Pathol. 2023;40:152–171. doi: 10.1053/j.semdp.2023.04.006. - DOI - PubMed
    1. Schwartz J.R., Ma J., Lamprecht T., Walsh M., Wang S., Bryant V., Song G., Wu G., Easton J., Kesserwan C., et al. The genomic landscape of pediatric myelodysplastic syndromes. Nat Commun. 2017;8:1557. doi: 10.1038/s41467-017-01590-5. - DOI - PMC - PubMed